Saturday 17 October 2026 Export PETV’s income statement to Excel — free account

PetVivo Holdings, Inc.

PetVivo Holdings, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, up 0.80% from fiscal 2025. In the quarter to June 2026, revenue grew 13.5%, EPS grew 44.4% and free cash flow grew 40.1%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

0.75 0.01 +1.35%

Follow PETV

Alert me

Market cap: $12.9M
P/E: 0.0×
Fwd P/E: −1.2×
Dividend yield: —
F-score: 3/9
Altman Z: −38.64
Beneish M: −8.74
Dividend safety: n/a

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.16

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	2	—	1	1	—	1	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 68.02%

Capital & Financial Ratios $m

Market Cap 12.93

Revenue 1.18

Net Income (9.78)

Free Cash Flow (5.45)

Net Debt (0.12)

Current Ratio 0.72

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.22)

P/S ratio 23.52

P/B ratio 20.57

Past 5Y EPS Growth —

This Y EPS Growth (14.12%)

Next Y EPS Growth 35.05%

Next Y revenue growth 818.76%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 27.92%

10-year low 10-year high

P/B against its own 10 years 67.14%

10-year low 10-year high

EV/Sales against its own 10 years 28.12%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	0	0	0	0
Receivables	0	4	1	0
Inventory	0	0	1	0
Other	—	—	—	—
	1	6	2	1

	2024	2025	2026	Q'26
Payables	1	1	1	0
ST’ Debt	—	—	—	—
Other	—	0	—	—
	1	4	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	146.28%	7.57%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(17.58%)	0.00%	44.76%

Revenue $m

	Sep	Dec	Mar	Year
’26	—	—	—	—
’26	0	0	0	1
’25	0	1	0	1
’24	0	1	0	1
’23	0	1	0	1
’22	0	0	0	0
’21	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(1)	—	—	—	—
’26	(2)	(2)	(1)	(1)	(6)
’25	(2)	(2)	(1)	(1)	(5)
’24	(2)	(2)	(1)	(2)	(7)
’23	(2)	(2)	(2)	(1)	(7)
’22	0	(1)	(1)	(2)	(4)
’21	0	0	0	0	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(1)	—	—	—	—
’26	(2)	(2)	(1)	(1)	(6)
’25	(2)	(2)	(1)	(2)	(6)
’24	(2)	(2)	(1)	(2)	(8)
’23	(2)	(2)	(2)	(1)	(7)
’22	0	(1)	(1)	(2)	(4)
’21	0	0	0	0	(1)

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	(0.05)	—	—	—	—
’26	(0.09)	(0.11)	(0.07)	(0.11)	(0.38)
’25	(0.11)	(0.11)	(0.09)	(0.11)	(0.41)
’24	(0.25)	(0.28)	(0.12)	(0.14)	(0.78)
’23	(0.20)	(0.21)	(0.23)	(0.21)	(0.85)
’22	(0.07)	(0.13)	(0.17)	(0.25)	(0.57)
’21	(0.16)	(0.23)	(0.16)	(0.04)	(0.57)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	0.22	1.03	0.56	0.49	2.36	1.20	0.55	0.29	0.45	0.59	Analyst estimates 2027–2029 Powerpack
	High	11.11	9.11	5.64	17.00	16.00	4.16	3.60	1.50	1.69	1.19
People
People	Employees	—	—	—	—	2	15	25	20	24	22
	Revenue/emp, $m	0.00	0.00	—	0.00	0.01	0.01	0.04	0.05	0.05	0.05
Income, $m
Income, $m	Revenue	0	0	—	0	0	0	1	1	1	1
	Gross margin, %	100.00	100.00	0.00	(447.22)	15.08	(74.05)	75.89	89.49	87.85	66.12
	EBT	(17)	(2)	(5)	(2)	(4)	(5)	(9)	(11)	(8)	(10)
	EBT margin, %	(232,700.00)	(155,820.00)	0.00	(57,852.78)	(27,958.73)	(4,338.24)	(950.46)	(1,130.93)	(741.65)	(917.46)
	Net income	(17)	(2)	(5)	(2)	(4)	(5)	(9)	(11)	(8)	(10)
	Depreciation	1	1	1	1	0	0	0	0	0	1
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.01	0.09	0.07	0.06	0.04
	Earnings	(7.68)	(0.65)	(1.00)	(0.38)	(0.57)	(0.57)	(0.85)	(0.78)	(0.41)	(0.38)
	Cash flow	(0.07)	(0.15)	(0.16)	(0.09)	(0.12)	(0.48)	(0.66)	(0.53)	(0.26)	(0.20)
	Capex	(0.02)	(0.01)	(0.02)	(0.01)	(0.03)	(0.02)	(0.04)	(0.02)	(0.03)	0.00
	Free cash flow	(0.09)	(0.16)	(0.18)	(0.11)	(0.15)	(0.50)	(0.71)	(0.55)	(0.29)	(0.20)
	Book value	0.41	0.04	(0.18)	(0.20)	(0.14)	0.68	0.07	0.05	0.21	0.07
	Shares, m	2	4	5	5	6	9	10	14	20	30
Valuation, ×
Valuation, ×	P/E	0.00	0.00	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	505.14	6,635.64	—	509.75	5,165.58	154.60	30.65	14.42	10.86	18.49
	P/B	4.38	179.74	—	0.00	0.00	2.99	38.78	20.36	2.92	9.62
	EV/Sales	511.79	6,591.12	—	583.77	5,182.36	102.05	30.40	14.35	10.53	18.32
	EV/FCF	(3.54)	(24.01)	—	(5.26)	(70.41)	(2.69)	(3.85)	(1.79)	(2.02)	(3.14)
Cash, $m
Cash, $m	Operating cash flow	0	(1)	(1)	0	(1)	(4)	(7)	(7)	(5)	(6)
	Capex	0	0	0	0	0	0	0	0	(1)	0
	Free cash flow	0	(1)	(1)	(1)	(1)	(4)	(7)	(8)	(6)	(6)
Balance, $m
Balance, $m	Working capital	(1)	(1)	(1)	(1)	(1)	6	0	0	1	0
	Total debt	0	0	0	0	0	0	0	0	0	—
	Net debt	0	0	0	0	0	(6)	0	0	0	0
	Shareholders’ equity	1	0	(1)	(1)	(1)	6	1	1	4	2
Returns, %
Returns, %	ROA	(167.13)	(134.92)	(421.25)	(343.23)	(518.94)	(121.39)	(176.71)	(394.48)	(134.88)	(168.43)
	ROIC	(834.44)	(1,545.79)	0.00	0.00	0.00	0.00	(1,115.10)	(1,085.05)	(130.88)	(306.41)
	ROE	(193.78)	(488.82)	1,343.63	221.45	364.45	(197.06)	(259.77)	(1,552.84)	(343.02)	(339.61)

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LFWD Lifeward Ltd.	$17.2M	— (loss-making)	— (loss-making)	+15.71% (above 0%: growing)	n/m	−52.77% (below 0%: shrinking)	40.90%	(62.69%)	Compare
ALUR Allurion Technologies, Inc.	$16.7M	— (loss-making)	— (loss-making)	−47.19% (below 0%: shrinking)	n/m	+65.98% (above 0%: growing)	41.70%	(126.60%)	Compare
HSCS HeartSciences Inc.	$15.4M	— (loss-making)	— (loss-making)	−46.15% (below 0%: shrinking)	n/m	+18.18% (above 0%: growing)	61.90%	(139,957.14%)	Compare
IRIX IRIDEX Corporation	$14.5M	— (loss-making)	— (loss-making)	−7.41% (below 0%: shrinking)	n/m	+130.24% (above 0%: growing)	34.19%	(8.19%)	Compare
RBOT Vicarious Surgical Inc.	$14.3M	— (loss-making)	—	—	n/m	+47.33% (above 0%: growing)	0.00%	0.00%	Compare
SINT SINTX TECHNOLOGIES, INC.	$13.4M	— (loss-making)	— (loss-making)	+199.34% (above 0%: growing)	n/m	−38.60% (below 0%: shrinking)	61.50%	(638.94%)	Compare
PETV PetVivo Holdings, Inc.	$12.9M	— (loss-making)	— (loss-making)	+13.48% (above 0%: growing)	n/m	+40.13% (above 0%: growing)	66.14%	(476.54%)
BTCY Biotricity Inc.	$10.9M	— (loss-making)	— (loss-making)	+10.40% (above 0%: growing)	n/m	+235.83% (above 0%: growing)	82.55%	3.70%	Compare
CTSO Cytosorbents Corporation	$9.7M	— (loss-making)	— (loss-making)	+0.17% (above 0%: growing)	n/m	+64.90% (above 0%: growing)	73.18%	(27.39%)	Compare
Median of peers	$14.4M	—	—	+0.17%	—	+56.12%	51.60%	(45.04%)

All 149 Medical Devices stocks →

PetVivo Holdings, Inc. (PETV) key facts

Strength: PetVivo Holdings, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, up 0.80% from fiscal 2025.
PetVivo Holdings, Inc. (PETV) is a Medical Devices company in the Healthcare sector.
As of October 16, 2026, PETV traded at $0.75, a market capitalization of $12.9 million.
Return on equity was −339.6% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −38.64 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.